Additionally, given the critical role of tumor mutation burden (TMB) in the immunotherapy response, we next investigated the prognostic relevance of NEK2 in immunologically “hot” pancreatic cancer with high or low TMB, respectively. The gene discussed is NEK2; the disease is familial pancreatic carcinoma.